Literature DB >> 14501854

Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury.

Masahide Matsuyama1, Rikio Yoshimura, Kiyokazu Akioka, Masahiko Okamoto, Hidetaka Ushigome, Yayoi Kadotani, Tatsuya Nakatani, Norio Yoshimura.   

Abstract

BACKGROUND: Tissue factor (TF) expression is induced on macrophages and endothelial cells during the immune response. We designed an antisense (AS) phosphorothioate oligodeoxynucleotide (ODN) to specifically inhibit the expression of rat TF to study the effects of the AS ODN on renal ischemia-reperfusion injury in the rat.
METHOD: AS-1 ODN for TF was delivered intravenously to inhibit the expression of TF in endothelial cells. After 8 hr, the right kidney was harvested and the left renal artery and vein were clamped. The kidney was reperfused after 90 min of ischemia, and rats were killed at 0, 1.5, 5, 12, and 24 hr after reperfusion. TF expression was analyzed by immunohistochemical staining using monoclonal antibody.
RESULTS: In the untreated ischemic group, 0 of 20 rats survived beyond day 3. However, treatment with AS-1/TF led to 12 of 20 rats surviving beyond day 4. TF was detected on distal tubular epithelial cells, endothelial cells, and blood vessels but not on necrotic and proximal tubular epithelial cells. The necrotic area extended and encompassed nearly all of the ischemic kidney within 12 hr after reperfusion. The necrotic area and the grade of TF staining were more significantly reduced in the AS-1/TF-treated group than in the control group. Furthermore, fluorescein isothiocyanate-labeled AS-1/TF was significantly intense in tubular epithelial cells 8 hr after intravenous administration.
CONCLUSIONS: The results indicate that AS-1/TF inhibited the ischemia-reperfusion injury of the kidney. Microcirculatory incompetence resulting from microthrombus may cause the formation and development of necrosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501854     DOI: 10.1097/01.TP.0000079630.68668.C2

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Pathophysiology of acute kidney injury.

Authors:  David P Basile; Melissa D Anderson; Timothy A Sutton
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

2.  Ischemia/reperfusion Injury and its Consequences on Immunity and Inflammation.

Authors:  Bendix R Slegtenhorst; Frank Jmf Dor; Hector Rodriguez; Floris J Voskuil; Stefan G Tullius
Journal:  Curr Transplant Rep       Date:  2014-09-01

Review 3.  Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule.

Authors:  G Girardi; N Mackman
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

Review 4.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

Review 5.  Renal endothelial dysfunction in acute kidney ischemia reperfusion injury.

Authors:  David P Basile; Mervin C Yoder
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2014

6.  Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.

Authors:  Ankit Mahendra; Ivan Peyron; Olivier Thaunat; Cécile Dollinger; Laurent Gilardin; Meenu Sharma; Bharath Wootla; Desirazu N Rao; Séverine Padiolleau-Lefevre; Didier Boquet; Abhijit More; Navin Varadarajan; Srini V Kaveri; Christophe Legendre; Sébastien Lacroix-Desmazes
Journal:  J Immunol       Date:  2016-04-11       Impact factor: 5.422

7.  Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury.

Authors:  Patricia Redecha; Rachel Tilley; Michael Tencati; Jane E Salmon; Daniel Kirchhofer; Nigel Mackman; Guillermina Girardi
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

Review 8.  Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.

Authors:  Bharath Wootla; Desirazu Narasimha Rao; Narasimha Rao Desirazu; Alain Friboulet; Taizo Uda; Sébastien Lacroix-Desmazes; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.